

**SUGGESTED FORMULA**

Fluconazole 100mg Troche

Version number: 1.0

Volume or quantity: 10 Troches

---

Fluconazole 100mg Tablets (commercial)*	#10
Colloidal Silicon Dioxide, NF, EP (S1510)	0.1 g
Stevia Leaves Extract, Sweet Powder (S1964)	0.075g
Acesulfame Potassium, NF (A3974)	0.05 g
Acacia, NF (GU115)	0.165 g
Citric Acid, USP, Anhydrous Granular (C1296)	0.115 g
Flavor, Choice	0.12 mL
Polyethylene Glycol 1450 MW, NF (P1492)	7.8 g

---

**This preparation should be compounded in a biological safety cabinet or compounding aseptic containment isolator.**

Calibrate Troche Mold and adjust formula as needed. This formula is based on approximately 1 g per troche. Flavors may be adjusted according to the patient's preference. Acesulfame Potassium works synergistically as a sweetener and can be added up to 0.5% or 5 mg per Troche. Do not increase Stevioside concentration beyond 7.5mg per Troche. Flavor oils may be added from 0.002 mL to 0.025mL per troche. Assume 80% displacement of PEG if powders are added or deleted.

**SUGGESTED COMPOUNDING PROCEDURES**

Weigh all ingredients

1. Spray mold cavities with non-stick cooking spray and drain excess into paper towel.
2. Select appropriately sized beaker and melt PEG at 50° to 55°C and stir.
3. Crush Fluconazole tablets and triturate to fine powder, add, Silica Gel, Stevioside, Acesulfame Potassium, Acacia and Citric Acid in mortar to fine powder.
4. Sift the powders into the melted PEG and stir until uniform.
5. Add the flavors and mix.
6. Pour into troche mold
7. Allow to congeal.
8. Suggested Quality assessments:
  - a. color, texture, appearance
  - b. troche cavity filled / not overfilled
  - c. mixing and filling/potency studies
  - d. Label - auxiliary labels, storage, BUD, compounded medication

Store in air-tight container, at Controlled room temperature.

No claims are made as to the safety or efficacy of this preparation. This formulation is provided solely at the unsolicited request of the pharmacist.

Beyond-Use Dates of preparations are conservative estimates from reference books, peer-reviewed literature, and intended duration of therapy, formulation from commercially available products, organoleptic observations and current USP guidelines. Compounders may have stability studies performed by a reputable laboratory if they wish to extend the Beyond-Use Date. It is recommended that you follow USP <795> recommendations for potency testing.

Beyond-Use Date estimated to be 180 days or as directed by the current USP <795> Standards

**Precautions:**

\*Hazardous drugs should be handled according to USP <800>, NIOSH standards and pharmacy SOPs. This preparation should be compounded in a biological safety cabinet or compounding aseptic containment isolator. Precautions should be taken to prevent cross-contamination and exposure of ingredients to the compounder and contamination of the preparation by the compounder. Wear appropriate personal protective equipment.

Although much attention has been paid to ensure the accuracy of the formulation contained here, Spectrum Pharmacy Products accepts no liability for the loss or damage arising from reliance on the information. Compounding pharmacists using this formula take full responsibility for the formulations and hold Spectrum Pharmacy Products and Spectrum Chemical Mfg Corp. and its officers, directors and employees harmless for any claim arising from use of or reliance on information contained therein.

3/19rd